Evidence map›Paper›PMID 28849221›Full record

ArticleOncology reports2017

TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear.

Paola Monti, Paola Ghiorzo, Paola Menichini, Giorgia Foggetti, Paola Queirolo, Alberto Izzotti, Gilberto Fronza

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Association betweenThe Journal of international medical research · 2022
    Pooled it
  2. Bioscience reports · 2018
    Pooled it
  3. Article
  4. p53 Family in Resistance to Targeted Therapy of Melanoma.International journal of molecular sciences · 2022
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. p63 Is a Promising Marker in the Diagnosis of Unusual Skin Cancer.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Paola MontiUOC Mutagenesis, Ospedale Policlinico San Martino, I-16132 Genova, Italy.
Paola GhiorzoDepartment of Internal Medicine and Medical Specialties, University of Genova, I-16132 Genova, Italy.
Paola MenichiniUOC Mutagenesis, Ospedale Policlinico San Martino, I-16132 Genova, Italy.
Giorgia FoggettiUOC Mutagenesis, Ospedale Policlinico San Martino, I-16132 Genova, Italy.
Paola QueiroloMedical Oncology Unit, Ospedale Policlinico San Martino, I-16132 Genova, Italy.
Alberto IzzottiUOC Mutagenesis, Ospedale Policlinico San Martino, I-16132 Genova, Italy.
Gilberto FronzaUOC Mutagenesis, Ospedale Policlinico San Martino, I-16132 Genova, Italy.
Ospedale Policlinico San Martino · ITUniversity of Genoa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In contrast to TP53, cancer development is rarely associated with mutations in the TP63 and TP73 genes. Recently, next generation sequencing analysis revealed that TP63 mutations are frequent, specifically in cutaneous melanomas. Cutaneous melanoma represents 4% of skin cancers but it is responsible for 80% of skin cancer related deaths. In the present study, we first determined whether all three members of the P53 family of transcription factors were found mutated in cutaneous melanomas by retrieving all TP53, TP63 and TP73 mutations from cBioPortal (http://www.cbioportal.org/). TP53 and TP63 were frequently mutated [15.0% (91/605) and 14.7% (89/605), respectively], while TP73 [1.5% (9/605)] was more rarely mutated (p<0.0001). A UV-mutation fingerprint was recognized for TP63 and TP73 genes. Then, we tried to evaluate the potential role of TP63 mutations as drivers or passengers in the tumorigenic process. In the former case, the amino acid substitutions should cause significant functional consequences on the main biochemical activity of the P63 protein, namely transactivation. The predicted effects of specific amino acid substitutions by two bioinformatics tools were rather different. Using a yeast-based functional assay, the observed hotspot mutant R379CP63 protein exhibited a substantial residual activity compared to the wild-type (>70%). This result does not support a major role of the mutant P63 protein in melanomagenesis while it is still consistent with the TP63 gene being a recorder of UV exposure. The TP63 mutation spectrum from cutaneous melanomas, when compared with that observed at the germinal level in patients affected by P63-associated diseases [ectodermal dysplasia syndromes, (EDs)], revealed significant differences. The TP63 mutations were more frequent at CpGs sites (p<0.0001) in EDs and at PyPy sites (p<0.0001) in cutaneous melanomas. The two spectra differed significantly (p<0.0001). We conclude that TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear.

Indexed as

MutationCarcinogenesisCutaneous Malignant MelanomaHumansMelanomaMolecular EpidemiologyNeoplasms, Radiation-InducedSkin NeoplasmsTranscription FactorsTumor Protein p73Tumor Suppressor Protein p53Tumor Suppressor ProteinsUltraviolet RaysTP53 protein, humanTP63 protein, humanTP73 protein, humanTranscription FactorsTumor Protein p73Tumor Suppressor Protein p53Tumor Suppressor Proteins

Identifiers

PMID28849221
PMCPMC5652947
OpenAlexW2749132130

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.